Washington University’s Center for Vaccines and Immunity to Microbial Pathogens (CVIMP) goal is to facilitate seamless interactions between the tremendous clinical expertise at Washington University School of Medicine (WUSM) and its world-renowned basic science departments.
Known pathogens, such as influenza viruses, HIV, TB, and malaria, and the emergence of new pathogens, such as the Zika virus and SARS-CoV-2, continue to represent frequent and significant threats to human health. Novel or improved vaccines and therapeutics are desperately needed across various infectious disease disciplines.
CVIMP targets all different stages of vaccine development that range from basic vaccine platform development, pivotal animal studies, detailed laboratory-based analysis of immune responses and correlates of protection, GMP production facilities, administrative infrastructure for IND filing, and a clinical trials group that can design and run phase I and II studies.
2024 Vaccine Center Symposium
Wednesday, November 13, 2024
Eric P. Newman Education Center, Washington University School of Medicine in St. Louis
Latest News
Our vision is to amplify and accelerate the translational impact of the cutting-edge research performed at WUSM that dissects the interplay between our immune system and microbial pathogens.
$12 million grant aimed at probing how vaccines induce lasting immunity (Links to an external site)
WashU Medicine leads 2 major pandemic preparedness research projects (Links to an external site)
